Clinical Trial Update: Study of TDXd, Chemotherapy, Pembrolizumab, and Trastuzumab in First-Line Metastatic HER2-Positive Gastric or Gastroesophageal Junction Cancer [Phase 3]

View source ↗

Summary

A Phase 3 clinical trial is evaluating a first-line combination of trastuzumab deruxtecan (TDXd), chemotherapy, pembrolizumab, and trastuzumab in metastatic HER…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gastric Cancer
• Gastroesophageal Junction Cancer

Drugs mentioned

• Pembrolizumab (pembrolizumab)
• Trastuzumab (trastuzumab)
• Trastuzumab deruxtecan (trastuzumab deruxtecan)

Snippet

Sponsor: Daiichi Sankyo | Conditions: Gastric Cancer, Gastroesophageal Junction Cancer | Phase 3 | Status: RECRUITING